Skip to main content

News

Optimizing Treat-to-Target in RA

Treat-to-target is a common management strategy for rheumatoid arthritis that aims to employ the strategy most effective in terms of achievement of optimal therapeutic outcomes in RA.

Healthcare Consumer Engagement Increasing

Deloitte published its 2015 Healthcare Consumer Survey to examine online resource and technology use by patients. This is important, as the health care industry has expanded the development of online information resources, mobile applications, and personal health devices.

Hip Fractures Increased in Rheumatoid Arthritis

An analysis of 741,589 patients over age 45 years from southern Swedish registry examined patients who were followed (between 1998 and 2012) until a hip fracture, death or exit from the region occurred.

Lupus Foundation of America Announces 2015 Award Recipients

Healio reported the newly announced grant recipients from the Lupus Foundation of America.

Diffuse Alveolar Hemorrhage in Lupus Reviewed

Diffuse alveolar hemorrhage (DAH) is a rare but catastrophic complication of systemic lupus erythematosus. Presentations are usually acute and the potential for significant morbidity and mortality risk mandates early diagnosis and aggressive interventions.

Angiogenic Biomarkers Predict Adverse Outcomes Pregnancies in Lupus

The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.

Physicians Bash Meaningful Use at Open Forum

Members of two professional medical societies griped about what they view as the Obama administration's inept attempts to regulate electronic health records (EHRs) and shared their visions for the ideal online platform at a second "town hall" meeting here Tuesday.

Strange ICD-10 Codes

The range of categories and diagnostic possibilities is astronomical with the new ICD-10 and its 68,000 codes.

Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis

AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.

Ustekinumab Effective in Adolescents with Psoriasis

Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,

Secukinumab Wins in Psoriatic Arthritis

Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).

TICOPA Study: Tight Control in Psoriatic Arthritis

Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.

Health Hazards of Fructose and Soda

The health consequences of fructose-containing sugars, sucrose and high fructose corn syrup, found in sugar-sweetened beverages and foods, may be numerous and include obesity, type 2 diabetes, gout and cardiovascular disease.

ICD-10: Preparing for the Next Y2K

ICD-10 starts tomorrow, October 1st. Your Coding memory will have to increase 5-fold or more as we go from 16,000 to 68,000 new ICD-10 codes. How this will affect each of us remains to be seen. There’s a lot to learn, and many wonder if this will be the next “Y2K”.

DSB: Drug Shortages - September 2015

RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins. Each month we will update you with reports of new, ongoing and resolved Drug Shortages that will affect the practicing rheumatologist.

×